Meeting Banner
Abstract #0287

Imaging assessment of pancreatic ductal adenocarcinoma xenograft treated with hypoxia activated prodrug Evofosfamide

Shun Kishimoto1, Nallathamby Devasahayam1, Yu Saida1, Yasunori Otowa1, Kazutoshi Yamamoto1, Jeffrey R Brender1, and Murali C Krishna1
1NCI, Bethesda, MD, United States

TH-302 is designed to release cytotoxic bromo-isophosphoramide (Br-IPM) moiety in hypoxic microenvironment. Therefore, this drug preferentially attacks the hypoxic region in cancer where other standard anti-cancer treatment such as chemotherapy and radiation therapy are ineffective. Here, we monitored the change in tumor hypoxia and perfusion in response to TH-302 treatment by EPR oximetry and DCE MRI using two pancreatic ductal adenocarcinoma xenograft models. The result showed improved oxygenation only in treatment sensitive MIA Paca-2 tumors without modulating tumor blood perfusion, suggesting that intratumor pO2 is a useful biomarker to evaluate treatment response to TH-302.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here